BTK inhibitors for MS, lecanemab, neurologic adverse effects and COVID vaccine
04/04/24 • 4 min
Neurology Today Editor-in-Chief Joseph E. Safdieh,MD, FAAN, highlights new research that casts doubt on the future of BTK inhibitors for MS, an assessment of the cost-effectiveness of lecanemab, and findings that COVID vaccines are not significantly associated with adverse neurologic events.
Neurology Today Editor-in-Chief Joseph E. Safdieh,MD, FAAN, highlights new research that casts doubt on the future of BTK inhibitors for MS, an assessment of the cost-effectiveness of lecanemab, and findings that COVID vaccines are not significantly associated with adverse neurologic events.
Previous Episode
SARS-CoV-2 and dopamine neurons, valproate risks for men, neurologists on locum tenens
Neurology Today Editor-in-Chief Joseph E. Safdieh, MD, FAAN, highlights new stories reporting on the impact of SARS-CoV2 on dopamine neurons, a European Medicines Agency warning about valproate risks for men, and neurologists on the pros and cons of working locum tenens.
Next Episode
ME/CFS and long COVID; negative outcomes for ALS drug; donanemab
Neurology Today Editor-in-Chief Joseph E. Safdieh,MD, FAAN, highlights new research that explores an association between myalgic encephalomyelitis/chronic fatigue and long COVID; negative phase 3 findings on AMX0035 for ALS, and the pending approval of donanemab for Alzheimer’s disease.
If you like this episode you’ll love
Episode Comments
Generate a badge
Get a badge for your website that links back to this episode
<a href="https://goodpods.com/podcasts/neurology-today-in-5-219983/btk-inhibitors-for-ms-lecanemab-neurologic-adverse-effects-and-covid-v-48093626"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to btk inhibitors for ms, lecanemab, neurologic adverse effects and covid vaccine on goodpods" style="width: 225px" /> </a>
Copy